Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOADET: High-dose vs Standard-dose Etanercept in AS
NCT00873730Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2006
- Primary completion
- Jun 2008
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 4, randomised, double-blind trial of etanercept in ankylosing spondylitis (AS) (2 arms), sponsored by Pfizer. Primary endpoint: Assessment in Ankylosing Spondylitis 20 Response at 12 weeks. Started Dec 2006; status: completed.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00873730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00873730.